Cadila Healthcare turns focus on vaccines and biosimilars

Analysts expect the two segments to contribute 25% of domestic revenue in 2 years; vaccines contribute less than 1% of revenues at present, while biosimilars account for 4.5% of domestic revenues

After setting its house in order for the US business, Cadila Healthcare is now putting focus on new areas with growth opportunities, such as biosimilars and vaccines. The Ahmedabad-headquartered pharma major at present draws less than one per cent of its domestic revenue from vaccines and about 4.5 per cent of its domestic turnover from biosimilars – analysts expect these two segments to contribute around 25 per cent to the company's domestic revenue in two years from now.

The company's Moraiya plant near Ahmedabad got clearance from the US drug regulator last year. Cadila Healthcare has bagged 70 approvals from